Fear not, AbbVie. Sales king Humira might have a graceful fall from biosim attack: analyst

Fear not, AbbVie. Sales king Humira might have a graceful fall from biosim attack: analyst

Source: 
Fierce Pharma
snippet: 

AbbVie’s top job today centers on developing new sources of revenue out of the fear that biosimilars to its megablockbuster Humira will cause a precipitous sales decline starting in 2023. But after analyzing prior cases, one team of analysts believes Humira might experience a more graceful fall than pharma watchers currently expect.